As the Democratic Republic of the Congo grapples with the fastest-growing Ebola outbreak on record, GeoVax Labs, Inc. (Nasdaq: GOVX) has stepped forward to highlight its potential contributions to the global response. The outbreak, caused by the Bundibugyo virus (BDBV), has already claimed over 2,000 lives and infected more than 4,300 people, with transmission continuing in conflict-affected areas. According to the World Health Organization (WHO), the trajectory could surpass the death toll of the 2014-2016 West Africa epidemic. No approved vaccine specifically targets Bundibugyo virus.
GeoVax, a biotechnology company developing vaccines and immunotherapies, possesses a portfolio of vaccine candidates against high-consequence hemorrhagic fever viruses, including Zaire ebolavirus, Sudan ebolavirus, and Marburg virus. These candidates, built on the Modified Vaccinia Ankara (MVA) platform, have demonstrated protective efficacy in non-human primate lethal-challenge studies. David Dodd, Chairman and CEO of GeoVax, stated, "The rapidly escalating Ebola Bundibugyo outbreak underscores the importance of having vaccine technologies and capabilities available before a crisis occurs. We are prepared to engage with WHO, Africa CDC, national public health authorities, and other appropriate organizations to determine whether our vaccine candidates, technology, or scientific expertise could contribute to the response."
GeoVax's primary infectious disease priority remains GEO-MVA, an MVA-based vaccine for mpox and smallpox, which is advancing under an expedited regulatory pathway. The company plans to initiate a pivotal immunobridging clinical program, with portions expected to be conducted in African regions, including areas affected by the current Ebola outbreak. These preparations have already led to engagements with healthcare and research organizations in the region, creating a natural opportunity to explore collaborative contributions to the Ebola response. Dodd added, "Our relationships in the region are being developed first and foremost to advance GEO-MVA, but many of the organizations with whom we are engaging are simultaneously confronting this Ebola outbreak. Given our experience, we believe it is appropriate to ask how we might help."
Besides GEO-MVA, GeoVax retains a broader MVA-based hemorrhagic fever vaccine portfolio, offering strategic optionality. The company is open to collaborations, licensing arrangements, and public-private partnerships that could provide resources for further development without diverting focus from GEO-MVA. "We are willing to make relevant vaccine materials available for evaluation against Bundibugyo virus," Dodd noted, emphasizing the foundation provided by MVA platform expertise and scalable manufacturing efforts.
The significance of GeoVax's offer lies in the urgent need for vaccines against Bundibugyo virus, which lacks an approved countermeasure. The company's existing candidates and platform could accelerate the development of a targeted vaccine, potentially mitigating the outbreak's impact. Moreover, the ongoing engagement in the region for GEO-MVA clinical trials positions GeoVax to contribute effectively to the public health response. As the outbreak evolves, collaborations between biotech firms and global health agencies will be crucial in containing this deadly virus.
